Compare Quest Diagnostics Inc (DGX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ulta Beauty Inc — how do they compare? Quest Diagnostics Inc trades at $230.39 (market cap $25.48B), while Ulta Beauty Inc trades at $562.3 (market cap $24.12B). The key difference: Quest Diagnostics Inc and Ulta Beauty Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Ulta Beauty Inc for 92 Days on average.
| DGX | ULTA | |
|---|---|---|
Market Cap | $25.48B | $24.12B |
Volume | 941,866 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $706.82 |
52-Week Low | $173.49 | $450.75 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | $31.23B | $26.43B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
ULTA Beauty trades at $545.48, down 0.33% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings beat and raised 2026 guidance, though Q4 2025 missed expectations. Valuation metrics show a P/E of 20.55 and P/S of 1.92, with robust profitability including 46.12% ROE. Analyst consensus is strongly bullish with 59.57% buy ratings and a $624.93 price target, representing 14.6% upside potential.
ULTA presents a compelling growth story with e-commerce momentum and expansion into wellness categories, though margin compression and flat traffic pose near-term challenges. The stock offers attractive upside to analyst targets but faces execution risks amid consumer spending pressures. Institutional ownership remains strong with recent buying activity from major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
